ACHIEVE LIFE SCIENCES, INC. [ACHV] - Achieve Life Sciences appoints Benjamin Halladay as CFO
Effective October 5, 2026, Achieve Life Sciences, Inc. appointed Benjamin Halladay as Chief Financial Officer, succeeding his previous role as CFO at Esperion Therapeutics, Inc.
Why this matters
Achieve Life Sciences, Inc., a company involved in the development of in vitro and in vivo diagnostic substances, has appointed Benjamin Halladay as its Chief Financial Officer, effective October 5, 2026. This appointment follows Halladay's tenure at Esperion Therapeutics, Inc., where he served as CFO and held various finance-related roles. The decision to bring Halladay on board does not appear to be driven by any specific external pressures or strategic shifts, as no rationale was provided in the announcement. Halladay's compensation package includes an annual base salary of $525,000, a discretionary bonus of up to 40% of his salary, and an option to purchase 200,000 shares of the company's common stock.